Timing of Colorectal Cancer Screening: How Current Guidelines Vary

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

In the phase 2 EPOCI1802 trial, atezolizumab monotherapy elicited a cCR rate of 42.1%, an ORR of 65.8%, and a 12-month OS rate of 65.8% in advanced ESCC.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Data from the phase 3 KEYNOTE-811 trial supported the FDA approval of this pembrolizumab combination in locally advanced unresectable or metastatic, PD-L1–positive, HER2-positive gastric or GEJ adenocarcinoma.

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.